脓毒症中的免疫检查点抑制:抗程序性细胞死亡配体1抗体(BMS-936559)的1b期随机安慰剂对照单次递增剂量研究
本研究为首次在脓毒症相关免疫抑制患者中评估抗程序性细胞死亡配体1(PD-L1)免疫检查点抑制剂BMS-936559的安全性、药代动力学及免疫生物标志物影响的1b期随机、安慰剂对照、剂量递增研究,在美国7个ICU进行,纳入24例脓毒症伴器官功能障碍且绝对淋巴细胞计数≤1,100 cells/μL的患者。患者接受单次BMS-936559(10-900 mg,n=20)或安慰剂(n=4)输注。主要终点为死亡和不良事件,关键次要终点包括受体占据率和单核细胞人类白细胞抗原-DR水平。总体死亡率为25%(10 mg组2/4;30 mg组2/4;100 mg组1/4;300 mg组1/4;900 mg组0/4;安慰剂组0/4)。所有患者均发生不良事件(75%为1-2级),17%发生严重不良事件(治疗组汇总3/20,安慰剂组1/4),均未判定为药物相关。54%的患者发生可能免疫相关的不良事件,多为1-2级,均无需使用皮质类固醇,且均未判定为药物相关。未观察到细胞因子水平的显著变化。BMS-936559(900 mg)在给药后28天内达到完全受体占据。在两个最高剂量下,观察到单核细胞人类白细胞抗原-DR表达明显增加(>5,000单克隆抗体/细胞),并持续超过28天。结论认为BMS-936559耐受性良好,无药物诱导的高细胞因子血症或细胞因子风暴的证据,较高剂量下显示28天内免疫状态恢复的迹象,需要进
要点
- 在脓毒症相关免疫抑制患者中,单次BMS-936559(10-900 mg)耐受性良好,未出现药物诱导的高细胞因子血症或细胞因子风暴。
- 总体死亡率为25%(10 mg组2/4;30 mg组2/4;100 mg组1/4;300 mg组1/4;900 mg组0/4;安慰剂组0/4)。
- 所有患者均发生不良事件(75%为1-2级),17%发生严重不良事件(治疗组汇总3/20,安慰剂组1/4),均未判定为药物相关。
- 54%的患者发生可能免疫相关的不良事件,多为1-2级,均无需使用皮质类固醇,且均未判定为药物相关。
- BMS-936559(900 mg)在给药后28天内达到完全受体占据;两个最高剂量下单核细胞人类白细胞抗原-DR表达明显增加(>5,000单克隆抗体/细胞)并持续超过28天。
适用人群与场景
- 纳入标准:脓毒症、器官功能障碍(低血压、急性呼吸衰竭和/或急性肾损伤)且绝对淋巴细胞计数≤1,100 cells/μL的参与者,来自美国7个医院ICU。
诊断标准与关键阈值
- 器官功能障碍定义:低血压、急性呼吸衰竭和/或急性肾损伤。
- 免疫抑制定义:绝对淋巴细胞计数≤1,100 cells/μL。
处置流程与药物剂量
- 单次静脉输注BMS-936559 10-900 mg(n=20)或安慰剂(n=4)。
- 主要终点为死亡和不良事件;关键次要终点包括受体占据率和单核细胞人类白细胞抗原-DR水平。
研究设计与关键结果
- 研究类型:1b期随机、安慰剂对照、单次递增剂量研究,在美国7个医院ICU进行,样本量24例。
- 干预与对照:单次BMS-936559(10-900 mg,n=20)或安慰剂(n=4)输注;治疗组汇总中位年龄62岁 vs 安慰剂组46岁;治疗组汇总55%有>2个器官功能障碍 vs 安慰剂组25%。
- 主要终点:总体死亡率25%(10 mg组2/4;30 mg组2/4;100 mg组1/4;300 mg组1/4;900 mg组0/4;安慰剂组0/4);所有患者均发生不良事件(75%为1-2级);17%发生严重不良事件(治疗组汇总3/20,安慰剂组1/4),均未判定为药物相关。
- 关键次要终点:可能免疫相关的不良事件发生于54%的患者,多为1-2级,均无需使用皮质类固醇,且均未判定为药物相关;未观察到细胞因子水平的显著变化;BMS-936559(900 mg)在给药后28天内达到完全受体占据;两个最高剂量下单核细胞人类白细胞抗原-DR表达明显增加(>5,000单克隆抗体/细胞)并持续超过28天。
证据类型、等级与局限
- 证据类型:1b期随机、安慰剂对照、单次递增剂量研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,BMS-936559在脓毒症相关免疫抑制患者中耐受性良好,无药物诱导的高细胞因子血症或细胞因子风暴的证据,较高剂量下显示28天内免疫状态恢复的迹象。
- 作者建议,需要进一步的随机试验评估程序性细胞死亡蛋白-1/程序性细胞死亡配体1通路抑制在脓毒症患者中的临床安全性和有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess for the first time the safety and pharmacokinetics of an antiprogrammed cell death-ligand 1 immune checkpoint inhibitor (BMS-936559; Bristol-Myers Squibb, Princeton, NJ) and its effect on immune biomarkers in participants with sepsis-associated immunosuppression.
DESIGN: Randomized, placebo-controlled, dose-escalation.
SETTING: Seven U.S. hospital ICUs.
STUDY POPULATION: Twenty-four participants with sepsis, organ dysfunction (hypotension, acute respiratory failure, and/or acute renal injury), and absolute lymphocyte count less than or equal to 1,100 cells/μL.
INTERVENTIONS: Participants received single-dose BMS-936559 (10-900 mg; n = 20) or placebo (n = 4) infusions. Primary endpoints were death and adverse events; key secondary endpoints included receptor occupancy and monocyte human leukocyte antigen-DR levels.
MEASUREMENTS AND MAIN RESULTS: The treated group was older (median 62 yr treated pooled vs 46 yr placebo), and a greater percentage had more than 2 organ dysfunctions (55% treated pooled vs 25% placebo); other baseline characteristics were comparable. Overall mortality was 25% (10 mg dose: 2/4; 30 mg: 2/4; 100 mg: 1/4; 300 mg: 1/4; 900 mg: 0/4; placebo: 0/4). All participants had adverse events (75% grade 1-2). Seventeen percent had a serious adverse event (3/20 treated pooled, 1/4 placebo), with none deemed drug-related. Adverse events that were potentially immune-related occurred in 54% of participants; most were grade 1-2, none required corticosteroids, and none were deemed drug-related. No significant changes in cytokine levels were observed. Full receptor occupancy was achieved for 28 days after BMS-936559 (900 mg). At the two highest doses, an apparent increase in monocyte human leukocyte antigen-DR expression (> 5,000 monoclonal antibodies/cell) was observed and persisted beyond 28 days.
CONCLUSIONS: In this first clinical evaluation of programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sepsis, BMS-936559 was well tolerated, with no evidence of drug-induced hypercytokinemia or cytokine storm, and at higher doses, some indication of restored immune status over 28 days. Further randomized trials on programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition are needed to evaluate its clinical safety and efficacy in patients with sepsis.
参考来源
- Hotchkiss RS, Colston E, Yende S, et al. Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559). Crit Care Med. 2019. PMID: 30747773. doi:10.1097/CCM.0000000000003685
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。